Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • R21/R33 Due Dates: Feb. 16, Jun. 16, Oct. 16
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

​PAR-18-084 Expiration Date September 8, 2019

Agency Website

Amount Description

For the R21 phase, the combined budget for direct costs during the two-year project period may not exceed $275,000 with no more than $200,000 requested in a single year. For the R33 phase, the direct costs should not exceed $500,000 per year.

The project period is limited to 2 years for the R21 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 16, 2019